Ensartinib

Drug Profile

Ensartinib

Alternative Names: X-396

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Xcovery
  • Developer Cancer Research Institute; Ludwig Institute for Cancer Research; MedImmune; Xcovery Holdings
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • No development reported Haematological malignancies

Most Recent Events

  • 01 Mar 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (PO) (NCT02898116)
  • 01 Mar 2017 Ludwig Institute for Cancer Research, MedImmune, Xcovery and Cancer Research Institute initiate enrolment in a phase I/II trial for Non-small cell lung Cancer (Monotherapy) in USA (NCT02898116)
  • 17 Jan 2017 Xcovery collaborates with NCI Formulary to co-develop ensartinib in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top